Small molecule · Activator of ecdysone receptor · developed by Alaunos Therapeutics
Veledimex is an orally bioavailable small molecule activator ligand that binds the ecdysone receptor (EcR) to activate the RheoSwitch Therapeutic System (RTS), an inducible gene regulation system. It stabilizes a heterodimer of Gal4-EcR and VP16-RXR fusion proteins, enabling controlled transcription of target genes. It is studied in melanoma, metastatic breast cancer, and pediatric brain tumors.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT03330197 | Phase 1/2 | Pediatric Brain Tumor | Terminated | TCRT |
| NCT02423902 | Phase 1/2 | Metastatic Breast Cancer | Terminated | TCRT |
| NCT01397708 | Phase 1/2 | Melanoma | Completed | TCRT |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Diffuse Intrinsic Pontine GliomaMelanomaMetastatic Breast CancerPediatric Brain Tumor
Updated Oct 3, 2026. Something wrong or missing? Report it on the TCRT page.
See TCRT's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
TCRT catalysts and pipeline →